Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRKPositive Net Change MRNAPositive Net Change ARQTPositive Net Change CGEMNegative Net Change

Zacks Equity Research

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

PFENegative Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

NVONegative Net Change MRKPositive Net Change MRNAPositive Net Change CTMXNegative Net Change